Product news

Share this article:
Canadian health officials have approved Merck's Januvia (sitagliptin phosphate monohydrate), a once-daily, oral medication in a new class of anti-hyperglycemic agents known as DPP-4 (dipeptidyl peptidase-4) inhibitors. Januvia is approved in combination therapy with metformin, a commonly prescribed diabetes medication, to improve blood sugar (glucose) control in adult patients with type 2 diabetes when diet and exercise plus metformin do not provide adequate glycemic control.     
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.